Ergoteles’s Xenetic Biosciences XBIO Stock Holding History

Ergoteles’s Portfolio XBIO Stock Details XBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,277	Closed	-$5.26K	–	1576
2023 Q1	$5.26K	Sell	1,277 -606	-32%	-$2.94K	﹤0.01%	1183
2022 Q4	$5.38K	Buy	+1,883	New	+$8.29K	﹤0.01%	1386

Other funds holding XBIO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NewSquare Capital Newtown Square, Pennsylvania $1.15B AUM 24.78% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ergoteles's XBIO Position: Q2 2023 in Review

Ergoteles sold out of Xenetic Biosciences (XBIO) in Q2 2023, closing a stake of 1,277 shares — an estimated $5.26K sold.

Ergoteles first reported a position in XBIO in Q4 2022 and held it in 2 quarters. The position peaked at $5.38K in Q4 2022. 9 funds tracked by Wall St. Rank hold XBIO as of Q2 2023.

Ergoteles reported no remaining Xenetic Biosciences position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 1,277 Xenetic Biosciences shares in Q2 2023, an estimated $5.26K.
Ergoteles first reported a position in Xenetic Biosciences in Q4 2022 and held it in 2 quarters.
Ergoteles's Xenetic Biosciences position peaked at $5.38K in Q4 2022.
9 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.